Skip to content

Study · Randomized controlled trial · n = 37 · 2011

7 results

The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.

Jiang J, Zhang J, Jacobsen LV, Hu P

Journal of clinical pharmacology27 Jan 2011Cited by 21 (Europe PMC)

PMID21273395 (opens in a new tab)DOI10.1177/0091270010389468 (opens in a new tab)PepBankPUB-21273395
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy Chinese subjects, liraglutide AUC(0-24h), Cmax and Ctrough at steady state did not deviate in a relevant way from dose proportionality across the 0.6, 1.2 and 1.8 mg doses.

    In plain wordsIn healthy Chinese subjects, liraglutide blood levels rose in proportion to the dose.

    Peptide
    Liraglutide
    Outcome
    No significant changeDose proportionality of AUC(0-24h), Cmax and Ctrough at steady state
    Study

    n = 37

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    The dose relationships of AUC(0-24h), C(max), and C(trough) at steady state do not deviate in a relevant way from dose proportionality
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy Chinese subjects, the median tmax of liraglutide was 8 hours.

    In plain wordsIn healthy Chinese subjects, liraglutide reached its peak blood level after a median of 8 hours.

    Peptide
    Liraglutide
    Outcome
    Not applicableTime to maximum concentration (tmax)
    Study

    n = 37

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Measurements

    tmax
    8 hours
    median

    Source sentences

    Summary
    t(max) and t(1/2) were 8 hours (median) and 11.2 to 12.2 hours (geometric mean), respectively.
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy Chinese subjects, the geometric mean half-life of liraglutide was 11.2 to 12.2 hours.

    In plain wordsIn healthy Chinese subjects, liraglutide had a half-life of 11.2 to 12.2 hours.

    Peptide
    Liraglutide
    Outcome
    Not applicableElimination half-life (t1/2)
    Study

    n = 37

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.6, 1.2 or 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Measurements

    t(1/2)
    11.2 to 12.2 hours
    geometric mean

    Source sentences

    Summary
    t(max) and t(1/2) were 8 hours (median) and 11.2 to 12.2 hours (geometric mean), respectively.
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy Chinese subjects, plasma glucose levels decreased in all liraglutide dose groups.

    In plain wordsIn healthy Chinese subjects, liraglutide lowered blood glucose at every dose.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma glucose
    Study

    n = 37

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6, 1.2 or 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    The plasma glucose levels in all liraglutide groups were decreased
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy Chinese subjects, serum insulin was reduced in the 1.2 and 1.8 mg liraglutide groups.

    In plain wordsIn healthy Chinese subjects, liraglutide at 1.2 and 1.8 mg lowered blood insulin.

    Peptide
    Liraglutide
    Outcome
    DecreaseSerum insulin
    Study

    n = 37

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 and 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    while reduced serum insulin level was observed in the 1.2- and 1.8-mg groups after liraglutide treatment.
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.
  6. 06HumanRandomized controlled trialSafety outcome

    In healthy Chinese subjects, the most common adverse events with liraglutide were of gastrointestinal origin.

    In plain wordsIn healthy Chinese subjects, the most common side effects of liraglutide affected the gut.

    Peptide
    Liraglutide
    Outcome
    Not applicableMost common adverse events
    Study

    n = 37

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.6, 1.2 or 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    The most common adverse events were of gastrointestinal origin.
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.
  7. 07HumanRandomized controlled trialSafety outcome

    In healthy Chinese subjects, adverse events other than gastrointestinal ones were comparable between the liraglutide and placebo groups.

    In plain wordsIn healthy Chinese subjects, other side effects were similar with liraglutide and with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther adverse events versus placebo
    Study

    n = 37

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.6, 1.2 or 1.8 mg once daily · subcutaneous · 21 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    Other adverse events were comparable between the liraglutide and placebo groups.
    1 context sentence
    Summary · context
    In this single-center, randomized, double-blind, within dose group, placebo-controlled, dose escalation trial, the pharmacokinetics, pharmacodynamics, tolerability, and safety of liraglutide were evaluated in 37 healthy Chinese subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00761540

To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo

Novo Nordisk A/Sn = 37Oct 2008 to Dec 2008

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.